title: Modulation of fluorouracil by methotrexate, leucovorin, and cisplatin (M-FLP) in the treatment of advanced pancreatic cancer: a phase II study of the Italian Oncology Group for Clinical Research (GOIRC).
abstract: The objective of this trial was to evaluate the activity and tolerability of biomodulation of 5-fluorouracil by leucovorin, methotrexate, and platinum in patients with advanced measurable disease. Thirty-five patients with histologically or cytologically proven adenocarcinoma of the pancreas were treated with methotrexate (100 mg/m2 in 500 ml 5% dextrose in a 2-hour infusion, day 1), 5-fluorouracil (800 mg/m2/day, i.v. in continuous infusion from days 2 to 5) plus 1-leucovorin (7.5 mg/m2 given per os every 6 hours, from days 2 to 5) and platinum (60 mg/m2 i.v., day 2), every 28 days. Four partial responses (12%; exact 95% confidence interval: 1-23%) were obtained in 34 evaluable patients with a median survival time of 49 weeks (range, 20-77 weeks). Ten (29%) of 34 patients had stable disease. Median time to treatment failure from the beginning of therapy was 11 weeks (range, 4-59 weeks) and median survival time was 20 weeks (range, 4-77 weeks). The most common grade III-IV toxicities were diarrhea (15%), stomatitis (41%), and vomiting (17%). Hematologic toxicity was mild. There were no therapy-related deaths. In conclusion, this trial did not report an increase or improvement in response rate and survival rates, and this regimen cannot be recommended as effective therapy for advanced pancreatic cancer.
authors.affiliation: Medical Oncology Institutions of Terni, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Di Costanzo
authors.forename: R
authors.initials: R
authors.lastname: Canaletti
authors.forename: A
authors.initials: A
authors.lastname: Sdrobolini
authors.forename: N
authors.initials: N
authors.lastname: Olmeo
authors.forename: G
authors.initials: G
authors.lastname: Luppi
authors.forename: F
authors.initials: F
authors.lastname: Pucci
authors.forename: F
authors.initials: F
authors.lastname: Cavicchi
authors.forename: S
authors.initials: S
authors.lastname: Gasperoni
authors.forename: C
authors.initials: C
authors.lastname: Rodinò
authors.forename: S
authors.initials: S
authors.lastname: Zironi
authors.forename: S
authors.initials: S
authors.lastname: Angiona
authors.forename: A
authors.initials: A
authors.lastname: Contu
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology; D007558:Italy; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D015996:Survival Rate; D017211:Treatment Failure
chemical_list: D007155:Immunologic Factors; D002945:Cisplatin; D002955:Leucovorin; D005472:Fluorouracil; D008727:Methotrexate